Published in AIDS Weekly, February 3rd, 1997
The data were from an ongoing Phase Ib/IIa double-blind, placebo-controlled trial designed to evaluate the safety and efficacy of repeated multiple oral doses of MKC-442 in HIV infected patients. A total of 26 patients were treated for up to two months.
Doses ranging from 100 to 350 mg twice a day were given to groups of six patients at each dosage level and additional patients currently are entering the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.